ChromaDex raises dosage of flagship Tru Niagen nicotinamide riboside following successful NDI notification

November 6, 2018

Following a successful New Dietary Ingredient (NDI) notification to FDA, ChromaDex has increased the capsule serving size of its flagship product Tru Niagen.

Following a successful New Dietary Ingredient (NDI) notification to FDA, ChromaDex (Los Angeles, CA) has increased the capsule serving size of its flagship product Tru Niagen (nicotinamide riboside) to 150 mg. Users are recommended to take two capsules per day, making the daily dosage 300 mg.

“We are pleased to offer Tru Niagen users a 300-mg daily serving of our revolutionary ingredient,” says Robert Fried, CEO of ChromaDex, in a press release. “This will provide an extra boost in NAD levels, which decline with age and the daily stressors of life.”

The product was studied clinically at 300 mg in 2016, with results published in the journal Nature Communications. Since then, says the firm, three additional studies have been published and 18 more studies are planned or in progress on the patented ingredient. This is Tru Niagen’s second successful NDI notification. The ingredient’s Generally Recognized as Safe status has also been filed with FDA.